Hana ʻo AASraw i nā pauka NMN a me NRC i ka nui!

Ceritinib (LDK378)

Rating: Māhele:

Hoʻohana ʻia ka Ceritinib Powder e mālama i nā mea maʻi me ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi (NSCLC) maikaʻi no ka anaplastic lymphoma kinase (ALK) a ke holomua nei nā ʻōpala a i ʻole hiki ke ʻae iā Crotinib (crizotinib).

Product Description

Nā ʻano kikoʻī

Product Name Ceritinib (LDK378) pauka
Kāleka CAS 1032900-25-6
Ka Lā Molecular C28H36CIN5O3S
Kaumaha Kaumaha 558.135
'O Synonyms LDK-378;

NVP-LDK378;

NVP-LDK378-NX;

5-Chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propan-2-ylsulfonyl)phenyl]pyrimidine-2,4-diamine.

Keʻano ʻO ka'ōmaʻomaʻo i ka paukūʻeleʻele
Ka mālama a me ka lima lima E mālama iā ia i ka mahana wela a mamao aku mai ka wela a me ka momona.

 

Ceritinib (LDK378) PaukaDescription

Hoʻohana ʻia ka paukū Ceritinib no ka mālama ʻana i nā mea maʻi me ka maʻi anaplastic lymphoma tum-positive (ALK +) metastatic non-liʻiliʻi cell cancer cancer (NSCLC) i ʻino a i ʻole hoʻomanawanui i crizotinib ma hope o ka mālama ʻana me crizotinib.

ʻO nā hoʻoponopono hou chromosomal e pili ana i ka anaplastic lymphoma kinase (ALK) ma ke ʻano he hoʻokele oncogenic ua hoʻololi maoli i ka mālama ʻia ʻana o ka maʻi ʻaʻai liʻiliʻi liʻiliʻi ʻole. I nā makahiki he 378 i hala aku nei, ua kupu mai nā lāʻau i mākaukau ʻia e like me kahi hoʻolālā pilikino pilikino kūpono no ka maʻi ʻaʻai liʻiliʻi liʻiliʻi ʻole ALK-hoʻoponopono hou ʻia. ʻO ka ʻae wikiwiki ʻana o nā mea kāohi ALK ikaika, e like me crizotinib a me ka paukū ceritinib (LDKXNUMX) hou aʻe, i hoʻokumu ʻia i nā hoʻokolohua hoʻolālā I / II i hoʻolālā maikaʻi ʻia he hopena kūleʻa i ka noiʻi maʻi ʻaʻai maʻi maʻi a hāʻawi i kahi wā hou o ka oncogenic target therapy i hōʻike ʻia e hoʻolālā hoʻolālā hoʻokolohua nani. ceritinib pauka e lilo i potent koho i crizotinib no ALK-hoʻoponopono hou ʻia ka liʻiliʻi-ʻāpana liʻiliʻi maʻi ʻaʻai.

 

Ceritinib (LDK378) pauka Ka hana hana

Hoʻohana ʻia ka paukū Ceritinib e mālama i nā mea maʻi me ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi (NSCLC) maikaʻi no ka anaplastic lymphoma kinase (ALK) a ke holomua nei nā tumors a ʻaʻole hiki ke hoʻomanawanui iā Crotinib (crizotinib).

ʻO Ceritinib ka paukū kahi mea koho a me ka mea pāpā i ka anaplastic lymphoma kinase (ALK). I ka physiology maʻamau, hana ʻo ALK ma ke ʻano he kī nui i ka hoʻomohala ʻana a me ka hana o nā pūnaewele nūhou. Eia nō naʻe, hāʻawi ka translocation chromosomal a me ka fusion i kahi ʻano oncogenic o ALK i hoʻopili ʻia i ka holomua o NSCLC. Hana ʻo Ceritinib ka pauma e kāohi i kēia enzyme mutated a hoʻōki i ka hoʻonui ʻana o ka cell, a ʻo ka hope ke kū nei i ka holomua o ka maʻi ʻaʻai. Ma muli o ka noʻonoʻo ʻia ʻana o ka paukū ceritinib he hopena maʻi ʻaʻai ponoʻī, koi ʻia kahi hōʻike i ʻāpono ʻia e FDA e hoʻoholo i nā mea maʻi i moho no ka paukū ceritinib. ʻO kēia hōʻike, hoʻomohala ʻia e Roche, ʻo ia ka VENTANA ALK (D5F3) CDx Assay a hoʻohana ʻia e ʻike i nā mea maʻi ALK-maikaʻi NSCLC e pōmaikaʻi ana i ka lāʻau ceritinib pauma.

 

Ceritinib (LDK378) Pauka noi

ʻO Ceritinib ka paukū kahi anaplastic lymphoma kinase (ALK) -hōpē mea hoʻohana i hoʻohana mua ʻia no ka mālama ʻana i ka metastatic NSCLC. Ma mua, ua hōʻike wale ʻia ia no nā mea maʻi i hoʻomohala kūʻē aku iā crizotinib, kahi mea kāohi ALK-maikaʻi, akā ua hoʻonui ʻia kāna hoʻohana e lawelawe ma ke ʻano he koho mua no ka metastatic NSCLC.

 

Ceritinib (LDK378) Pauka Nā ʻaoʻao a me nā ʻōlelo aʻoaʻo

ʻO nā hopena maikaʻi ʻole e pili ana i ka ʻona gastrointestinal, hepatotoxicity, maʻi lele interstitial, hoʻolōʻihi ʻia ka QT syndrome, hyperglycemia, bradycardia, a me pancreatitis.

ʻO nā hopena i hōʻike pinepine ʻia ʻo ka diarrhea, nausea, nā enzymes kiʻekiʻe o ke ake, ka luaʻi, ka ʻeha o ka ʻōpū, ka luhi, ka hōʻemi ʻana i ka makemake, a me ka constipation. Ma muli o ka makaʻu o nā ʻenema ate kiʻekiʻe, pono e hoʻokō ʻia nā hoʻokolohua hana ate i kēlā me kēia ʻelua pule no 9 mau pule mua o ka mālama ʻana.

ʻO ka mea hope loa, ʻo ka paukū ceritinib he substrate a me ka mea pāpā i ka enzyme CYP3A4, no laila e nānā pono ʻia nā lāʻau i hiki ke launa me ka paukū ceritinib.

 

Kāhea pū i kāu kauka i ka manawa inā loaʻa iā ʻoe:

▪ ʻōpū nui loa;

▪ ʻeha poʻo, huikau, hoʻololi i ke kūlana noʻonoʻo, nalo ʻana o ka hihiʻo, hopu ʻana (haʻalulu);

▪ liʻiliʻi a ʻaʻohe paha urination;

▪ kahe koko ʻole (kahe ʻana o ka ihu, ke kahe nui o ka menstrual), a i ʻole nā ​​kahe ʻē aʻe e kū ʻole.

▪ hōʻailona o ke kahe ʻana o ka ʻōpū – ke koko a i ʻole nā ​​pā noho, hoʻoheʻe i ke koko a i ʻole ka luaʻi e like me ke kope;

▪ nā pilikia puʻuwai – ʻeha o ka umauma, ʻeha ma kou āwae a i ʻole ʻūhā, pehu, loaʻa ke kaupaona wikiwiki, ʻano hanu ʻole;

▪ nā hōʻailona o ke kōkō ʻana i ke koko – ka helu a me ka nāwaliwali koke, nā pilikia me ka hihi a me ka ʻōlelo;

▪ nā pilikia o ke ake ake – mimi ʻeleʻele, nā noho pā kalai i ka pālolo, nā ʻōpala ʻeleʻele (melemele o ka ʻili a me nā maka);

▪ haʻahaʻa pae pae kalima –hoʻopaʻa a hōʻemi paha nā puʻupuʻu, numbness a i ʻole ʻano manamana (a puni kou waha, a i ʻole i kou manamana lima a me kou manamana wāwae);

▪ hoʻonui i ke kahe o ke koko – ʻeha ke poʻo, ʻike maka ʻole, kuʻi i kou ʻāʻī a pepeiao paha, hopohopo, ihu.

E hoʻopaneʻe a hoʻopau ʻia paha kāu mau maʻi maʻi maʻi inā loaʻa iā ʻoe kekahi mau hopena ʻaoʻao.

 

Reference

[1] “Zykadia (ceritinib pauka) Capsules, no ka hoʻohana waha. ʻIkepili Kauoha piha ”(PDF). ʻO Novartis Pharmaceors Corporation. Ua kiʻi ʻia 14 Pepeluali 2017.

[2] "Nā inoa Nonproprietary honua no nā mea lāʻau (INN). Koi ʻia nā inoa inoa ʻole kūloko o ka honua: papa inoa 71 "(PDF). Ka Hui Ola Ola Honua. 2014. p. 79. Ua kiʻi ʻia 14 Pepeluali 2017

[3] "ʻAe ʻo FDA i ka paukū Ceritinib no ka maʻi maʻi maʻi maʻi ALK-Positive Lung". Medscape. 29 ʻApelila 2014.

[4] "Ke kuhikuhi nei i ka ʻikepili" (PDF). www.paula.pa.novartis.com. Ua kiʻi ʻia 2019-06-12.

[5] "Hoʻonui ka FDA i ka Ceritinib paukū ʻae no ka maʻi ʻaʻai puʻu". Ke Kula Kaiapuni ʻAi Moku. 27 Iune 2017.


  • RegorafenibFree heluhelu hou
  • IbrutinibFree heluhelu hou
  • NeratinibFree heluhelu hou